Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05712746

Samtasu Post-marketing General Drug Use-results Survey in Patients with Volume Overload in Heart Failure.

Sponsor: Otsuka Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

1600

Start Date

2023-03-03

Completion Date

2026-05-31

Last Updated

2025-03-21

Healthy Volunteers

Conditions

Heart Failure

Interventions

DRUG

Samtasu for I.V. infusion

Drug: 8 mg/vial or 16mg/vial Dosage and Administration: The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour.

Locations (1)

Pharmacovigilance Department

Osaka, Japan